ArticleBiochemistry and biophysics reports2026
Metabolic phenotype and patient characteristics associate with inter-donor variability of osteogenic differentiation in human adipose stem cells.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipose-derived stem/stromal cells (ASCs) are promising candidates for bone tissue engineering due to their abundance, accessibility, and osteogenic differentiation capacity. However, substantial inter-donor variability limits their standardized clinical application. This study investigated whether metabolic characteristics and donor-related parameters are associated with ASC osteogenic differentiation potential. ASCs were isolated from human subcutaneous adipose tissue (n = 26) and cultured under osteogenic conditions. Cell viability was evaluated at days 2 and 14, including cell proliferation (crystal violet staining), overall metabolic activity (resazurin conversion), as well as glucose uptake (2-NBDG) and mitochondrial membrane potential (TMRE). Osteogenesis was quantified by alkaline phosphatase activity, calcium deposition, and secretion of SPARC and osteocalcin (BGLAP). Osteogenic induction significantly enhanced osteogenic markers and mineralization across donors and was accompanied by a distinct metabolic phenotype characterized by reduced per-cell metabolic activity and glucose uptake, and elevated mitochondrial membrane potential. Early (day 2) metabolic parameters did not predict subsequent mineralization capacity, whereas metabolic activity at day 14 correlated inversely with calcium deposition. Donor age, body mass index, and blood glucose levels were not associated with osteogenic outcomes. These findings indicated that inter-donor variability in ASC osteogenesis was accompanied by a characteristic late-stage metabolic signature and suggested that metabolic profiling may support functional characterization of osteogenic differentiation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.